Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides

[PR Newswire] – CRANBURY, N.J., March 19, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases … more

View todays social media effects on PTN

View the latest stocks trending across Twitter. Click to view dashboard

See who Palatin is hiring next, click here to view